


Amendments to the Claims

This listing of claims replaces all prior versions, and listings of claims in the application.

Claims 1-12 are cancelled. The following new claims have been added:

13. (New) Beta-secretase inhibitor of formula (I)



wherein

X represents a methyl, a trifluoromethyl, F, Cl, Br, or I;

R_1 independently represents a halogen, a hydroxyl, a cyano, a trifluoromethyl, a nitro, or a hydrocarbon group containing 1 to 4 carbon atoms, wherein $n = 0$ to 4;


R_2 is a connecting moiety consisting of $-\text{CH}=\text{N}-\text{NR}^8-$ and $-\text{C}(\text{CH}_3)=\text{N}-\text{NR}^8$,

wherein $\text{R}^8 = \text{H}$;

Cyc represents an aryl or heterocyclic moiety;

R_3 is independently a group being bound to Cyc, wherein R_3 is selected from R_1 or an aryl or heterocyclic moiety substituted by 0 to 4 moieties from R_1 , wherein $m = 0$ to 8;

with the proviso that beta-secretase inhibitor of formula (I) is not




and with the proviso that when $n = 0$ and R_1 is a methyl, Cl, F, or CF_3 ,

then R_3 is not Cl or methyl and m is not 2.


14. (New) Beta-secretase inhibitor according to Claim 13, wherein R_1 is a unsubstituted or a substituted C1-C4 alkyl.

15. (New) The Beta-secretase inhibitor according to Claim 14, wherein R_1 is a C1-C4 alkyl substituted with hydroxyalkyl, carboxyalkyl, acylalkyl, oxyalkyl, sulfonylamidoalkyl, or amidoalkyl.

16. (New) Beta-secretase inhibitors according to Claim 13, wherein Cyc is selected from the group consisting of




17. (New) Beta-secretase inhibitors according to Claim 13 having the formula



18. (New) Beta-secretase inhibitor according to any of the Claims 13 to 17 having $IC_{50} \leq 200 \mu M$.
19. (New) Beta-secretase inhibitor according to Claim 18 being active in the cells.
20. (New) A pharmaceutical composition comprising a beta-secretase inhibitor according to Claim 13 optionally in admixture with one or more pharmaceutically acceptable carriers, diluents and/or excipients.
21. (New) The process for the manufacture of a pharmaceutical agent for the treatment or prevention of a condition which is mediated by beta-secretase comprising mixing beta-secretase inhibitor according to Claim 13 with one or more pharmaceutically acceptable excipients.
22. (New) The process for the manufacture of a pharmaceutical agent for the treatment or prevention of a condition which is mediated by beta-secretase of Claim 21 comprising the inhibition of the formation of beta amyloid peptides from the amyloid precursor protein (APP).
23. (New) The process for the manufacture of a pharmaceutical agent for the treatment or prevention of a condition which is mediated by beta-secretase of Claims 22 further comprising the modulation of the activity of the beta-amyloid converting enzyme.
24. (New) The process for the manufacture of a pharmaceutical agent for the treatment or prevention of a condition which is mediated by beta-secretase as in any of Claims 21 to 23, wherein the condition is selected from the group consisting of Alzheimer's disease or any disorder caused by pathological deposits of beta amyloid peptides using beta-secretase inhibitor, Down syndrome, cerebral amyloid angiopathy, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D) and other degenerative dementia characterized by beta-amyloid deposits.

25. (New) The method for the manufacture of a pharmaceutical agent for the treatment or prevention of a condition which is mediated by beta-secretase of Claim 24, wherein the condition is Alzheimer's disease or any disorder caused by pathological deposits of beta amyloid peptides using beta-secretase inhibitor.
26. (New) A method for the treatment or prevention of conditions which is mediated by beta-secretase comprising the administering a therapeutically effective amount of a compound of formula:



or pharmaceutically acceptable salt thereof.

27. (New) The method for the treatment or prevention of conditions of Claim 26 comprising the inhibition of the formation of beta amyloid peptides from the amyloid precursor protein (APP).
28. (New) The method for the treatment or prevention of conditions of Claim 27, further comprising the modulation of the activity of the beta-amyloid converting enzyme.
29. (New) The method for the treatment or prevention of conditions as in any of Claims 26-28, wherein the condition which is mediated by beta-secretase is selected from the group consisting of Alzheimer's disease or any disorder caused by pathological deposits of beta amyloid peptides using beta-secretase inhibitor, Down syndrome, cerebral amyloid

angiopathy, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch type (HCHWA-D) and other degenerative dementia characterized by beta-amyloid deposits.

30. (New) The method for the treatment or prevention of conditions of Claim 29, wherein the condition which is mediated by beta-secretase is Alzheimer's disease or any disorder caused by pathological deposits of beta amyloid peptides using beta-secretase inhibitor.